Article Text

other Versions

PDF
Letter
Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease
  1. Jun Liang,
  2. Huayong Zhang,
  3. Dandan Wang,
  4. Xuebing Feng,
  5. Hong Wang,
  6. Bingzhu Hua,
  7. Bujun Liu,
  8. Lingyun Sun
  1. Department of Immunology and Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
  1. Correspondence to Dr Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, Jiangsu 210008, China; lingyunsun2001{at}yahoo.com.cn

Statistics from Altmetric.com

We refer to two articles by Duijvestein et al and Ciccocioppo et al1 2 in which the authors suggest that administration of autologous bone marrow-derived mesenchymal stem cells (MSCs) is safe and feasible in the treatment of refractory Crohn's disease (CD). However, to date there are few data about allogeneic MSC transplantation (MSCT) for patients with inflammatory bowel disease (IBD).

We wish to report our experience of allogeneic MSCT in seven patients with IBD.

Infused allogeneic MSCs were obtained from the bone marrow or umbilical cord. Bone marrow was aspirated from healthy relatives of three patients. Umbilical cords were obtained from local maternity hospitals after normal deliveries. The isolated MSCs were given by intravenous infusions …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.